COMPANY

ModeX Therapeutics

HQ: Weston, MA source · modextherapeutics.com ↗

Keywords: antibody RNA therapeutics cell therapy oncology lipid nanoparticle LNP mRNA influenza COVID -19 COVID-19 (Prevention) Biliary Tract Cancer Breast Cancer Cervical Cancer Colon Cancer Endometrial Cancer Esophageal Cancer Gastric Cancer GastroEsophageal Cancer Head and Neck Cancer Hepatocellular Cancer Non-small Cell Lung Cancer Pancreatic Cancer Prostate Cancer Rectal Cancer Renal Cancer Thyroid Cancer Lymphoma Waldenström Macroglobulinemia DLBCL - Diffuse Large B Cell Lymphoma FL Lymphoma Lymphoplasmacytic Lymphoma Follicular Lymphoma MDX2301 MDX2001 MDX2003 MDX2004

Location: Weston, MA · source · Oct 12, 2026

Profile checked Oct 10, 2026

4Trials (company is sponsor)

Raises and deals from press releases

Deal Regeneron deal · up to $1B total · announced Oct 29, 2025 Company release ↗
Source quote
- Oct 29, 2025 · Company release ↗
  “Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) — ModeX Therapeutics Inc.”

From the company’s own releases; this list is partial. All raises and deals

Timeline

Apr 13, 2026 Trial start Phase 1/Phase 2: Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma source ↗
Mar 24, 2026 Trial start Phase 1: A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19. source ↗
Oct 29, 2025 Partnership Partnership / licensing announced Oct 29, 2025. Source: company's own press page. source ↗
Oct 1, 2025 Trial start Phase 1/Phase 2: Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors source ↗
Jun 12, 2024 Trial start Phase 1/Phase 2: Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors source ↗

Upcoming milestones

2027-09 (ESTIMATED) · Phase 1 · A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19. · NCT07445971
2028-01 (ESTIMATED) · Phase 1/Phase 2 · Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma · NCT07249905
2028-08 (ESTIMATED) · Phase 1/Phase 2 · Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors · NCT06239194
Jun 30, 2031 (ESTIMATED) · Phase 1/Phase 2 · Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors · NCT07110584

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Oct 29, 2025 Partnership / licensing announced Oct 29, 2025. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT07445971	A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.	Phase 1	Recruiting	Mar 24, 2026	2027-09 (estimated)
NCT06239194	Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors	Phase 1/Phase 2	Recruiting	Jun 12, 2024	2028-08 (estimated)
NCT07249905	Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma	Phase 1/Phase 2	Recruiting	Apr 13, 2026	2028-01 (estimated)
NCT07110584	Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors	Phase 1/Phase 2	Recruiting	Oct 1, 2025	Jun 30, 2031 (estimated)